Fifty-two elderly glaucomatous patients, without a history of asthma or obstructive airways
disease, who were using topical timolol for control of intraocular pressure were recruited …

Timolol, a β-adrenergic blocking agent, recently became available for the treatment of
glaucoma. We report the occurrence of acute bronchospasm in a previously asymptomatic …

Beta-blocker eyedrops used on asthmatic patients are known to enhance asthma which is,
as chronic bronchitis, an obstructive disease of the lung, and an authentic …

This open study of beta blockers in chronic simple glaucoma compared the efficacy of once
daily (od) oral nadolol therapy with twice daily (bd) topical timolol therapy. Sixty eight …

Topical glaucoma therapies may induce adverse systemic side effects. This study was
designed to determine the potential for drug-induced cardiovascular side effects of various …

Chronic simple glaucoma is a common disease in old age and lowering intraocular pressure
is the treatment strategy. Although this can be achieved surgically, medical treatment with …

This set of Viewpoints articles examines the merits of beta-blockers versus other
medications as the primary drug treatment for glaucoma. Ophthalmologists must balance …

The safety profile of the different glaucoma medications is an important issue when initiating
therapy in glaucomatous patients. The decision on which medication to prescribe depends …

Topical β blockers are the most commonly prescribed drugs in the United Kingdom for
glaucoma. 1 They are known to exacerbate bronchospasm in asthma and chronic …

Timolol maleate, the first B-adrenergic antagonist available for the treatment of glaucoma
and ocular hypertension, was marketed in 1978 (1). Shortly after its introduction, systemic …